Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 15/20 | 0.48 |
| ▸ | CCNY | Q8ND76 | 13/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CASK | O14936 | 1/20 | 0.45 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | MAK | P20794 | 1/20 | 0.45 |
| ▸ | CDK11B | P21127 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993660 | 0.94 | LMNA (0.46) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8262596 | 0.94 | CDK14 (0.43) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8261492 | 0.94 | CDK2 (0.49) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8263999 | 0.93 | CDK14 (0.52) | CDK14CCNYLMNARAB9ACNR1 | |
| SCHEMBL8261500 | 0.91 | CDK14 (0.43) | CDK14CCNYLMNARAB9ACNR1 | |
| SCHEMBL2031219 | 0.91 | CDK14 (0.51) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8261512 | 0.91 | CDK14 (0.44) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8262996 | 0.90 | CDK14 (0.47) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8261501 | 0.90 | CDK14 (0.45) | CDK14CCNYCNR1 | |
| SCHEMBL8262985 | 0.90 | CDK14 (0.47) | CDK14CCNYCCNT1CDK9CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | claimed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | claimed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | claimed |
| EP-2027109-A1 | 4- (2, 6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-S-CARBOXYLIC ACID (1-METHANESULPH0NYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | Astex Therapeutics Limited (GB) | 2009-02-25 | — | — | EP | claimed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| EP-2562265-A1 | Susceptibility to selective CDK9 inhibitors | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK14 21/4885CCNY 59/4885CCNT1 41/4885 |
| US-20140303167-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | CDK14 21/4885CCNY 59/4885CCNT1 41/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | CDK14 1723/4885CCNY 748/4885CCNT1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.